Issued by the Japanese Patent Office
A New Protection Covering Tedopi® Until 2037
NANTES,
This new patent recognises the innovation of a multiepitope composition (all peptides included in Tedopi®) administered after immune checkpoint inhibitor (progression of the cancer), in particular in secondary resistance situation.
“This first notice of allowance for a Japanese patent for Tedopi® after failure with immune checkpoint inhibitors, issued in a significant territory, is of major interest and is the first step to the corresponding patent family that has been filed internationally in many other territories.
“In addition, it further supports the product’s clinical development focus and the positive results of the
The
Tedopi® demonstrated a favourable benefit/risk ratio versus standard of care (SoC) docetaxel or pemetrexed in advanced HLA-A2 positive NSCLC patients with secondary resistance to PD-1 or PD-L1 immune checkpoint inhibitors.
ABOUT
Lung cancer is the leading cause of cancer death (18.0% of the total cancer deaths) with an estimated 2.2 million new cancer cases per year and with 1.8 million deaths(1). About 85% of lung cancers are Non-Small Cell Lung Cancers (NSCLC) and for metastatic NSCLC, the 5-year survival rate is 7%(2).
Treatment regimens including immune checkpoint inhibitors (ICIs) have become the new standard of care for the majority of patients with NSCLC. However, with the increasing use of ICIs in clinical practice, disease progression can be observed in several patients. This therapeutic escape is described as a secondary resistance(3) when it occurs after initial clinical benefit under ICI treatment. Over half of the patients will eventually develop secondary resistance to ICIs(4).
1 - Sung H et al , CA Cancer J Clin 2021 (GLOBOCAN 2020 –
2 -
3 - Zhou B et al. Front Immunol 2021 Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.
4 - Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020 Apr 13.
ABOUT
Vaccine platform
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer patients after secondary resistance to checkpoint inhibitors.
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT. - CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Clinical data (
Nov. 2021 ) validating the multi-target vaccine show good tolerance and promising efficacy signals. Results from 6-month memory T cell responses expected Q1 2022.
- BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening. - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
- BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Autoimmunity and inflammation platform
- FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the
Nantes University Hospital ); Phase 2-ready asset in an autoimmune disease indication. - OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a ongoing in Sjögren’s syndrome (Servier sponsor). - OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information: https://ose-immuno.com/en/
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations thomas.guillot@ose-immuno.com +33 607 380 431 | Media darren@lifescicomms.com +1 646 627 8387 French Media: FP2COM fportejoie@fp2com.fr +33 607 768 283 | gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the
![](https://ml.globenewswire.com/media/MTYwNzliZWYtMjc4Yi00MzcwLTg5MGUtODY1MjRhYmI0MGY1LTEwOTQ1NTg=/tiny/OSE-Immunotherapeutics.png)
2022 GlobeNewswire, Inc., source